Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging therapies for multiple sclerosis.

Paolo A Muraro1, Bibiana Bielekova

  • 1Department of Cellular and Molecular Neuroscience, Imperial College London, London SW7 2AZ, United Kingdom. p.murano@imperial.ac.uk

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|October 9, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Should autologous HSCT be a first-line option in highly active MS: YES.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Clinical and biochemical characterization of amyotrophic lateral sclerosis in a CHCHD10 R15L family.

Brain : a journal of neurology·2026
Same author

Assessing verbal and spatial memory via smartphone.

Frontiers in digital health·2026
Same author

A tight match: comparing the effectiveness of immune reconstitution therapies for multiple sclerosis.

Brain : a journal of neurology·2026
Same author

Extrapolating from trials to clinic: a predictive model defining the boundaries of benefit for multiple sclerosis therapies in real-world populations based on systematic review.

BMC medicine·2026
Same author

Longitudinal proteomic profiling of cerebrospinal fluid in untreated multiple sclerosis defines evolving disease biology.

Nature communications·2025
Same journal

PrP<sup>C</sup> modulates BACE1-dependent amyloid pathology under chronic cerebral hypoperfusion: Implications for vascular cognitive impairment.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Contemporary surgical strategies for resection of intracranial gliomas.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

FGF17 synergistically targets neuronal survival and oligodendrogenesis to restore stroke deficits.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Sotagliflozin improves cognitive deficits and attenuates neuroinflammation of Alzheimer's disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Neurological complications of current and emerging CAR-T cell therapies.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Hemodynamics Beyond Ischemic Zone Underlies Early Neurological Deterioration in Minor Stroke with Large Vessel Occlusion.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
See all related articles

Emerging immunotherapies show promise for multiple sclerosis (MS) treatment. Strategies like stem cell transplantation and targeted monoclonal antibodies offer new hope for managing this complex neurological disease.

Area of Science:

  • Neuroimmunology
  • Clinical Therapeutics
  • Regenerative Medicine

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Current treatments primarily focus on immunomodulation and immunosuppression, with limitations in efficacy and side effects.
  • There is a critical need for novel therapeutic strategies that offer improved outcomes and potential for disease modification.

Purpose of the Study:

  • To review the mode of action, safety, and clinical efficacy of novel therapeutic strategies for multiple sclerosis.
  • To explore the potential of emerging immunotherapies, including stem cell transplantation, targeted therapies, and regenerative approaches.
  • To assess the progress in developing effective treatments for multiple sclerosis.

Main Methods:

Related Experiment Videos

  • Review of current literature on advanced multiple sclerosis therapies.
  • Analysis of mechanisms of action for various immunomodulatory and regenerative treatments.
  • Evaluation of clinical efficacy and safety profiles of emerging therapies.

Main Results:

  • Autologous hematopoietic stem cell transplantation shows potential as a rescue therapy for aggressive MS.
  • High-dose cyclophosphamide may induce remissions with reduced toxicity.
  • Novel oral agents like Fingolimod (FTY720) and monoclonal antibodies targeting specific molecules (alemtuzumab, daclizumab, natalizumab, rituximab) demonstrate potent immunomodulatory effects.
  • Investigational therapies, including immunoglobulins for remyelination, are being explored for tissue repair.

Conclusions:

  • Significant progress is being made in developing effective treatments for multiple sclerosis.
  • Emerging immunotherapies offer diverse mechanisms to combat MS, from immune system regeneration to targeted molecular intervention.
  • Future research directions include promoting tissue repair and functional recovery, aiming for potential cures for MS.